Improvements in bone density and structure during anti-TNF-α therapy in pediatric Crohn's disease

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 7, 2015, Pages 2630-2639

  Griffin, Lindsay M ^a   Thayu, Meena ^b   Baldassano, Robert N ^c   DeBoer, Mark D ^d   Zemel, Babette S ^c   Denburg, Michelle R ^c   Denson, Lee A ^e   Shults, Justine ^e   Herskovitz, Rita ^b   Long, Jin ^b   Leonard, Mary B ^c,f,g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; AGE; ARTICLE; BODY HEIGHT; BONE DENSITY; BONE STRUCTURE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; CROHN DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE; OSSIFICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; SCORING SYSTEM; SEX DIFFERENCE; TRABECULAR BONE; Z SCORE; ANTAGONISTS AND INHIBITORS; BONE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; LONGITUDINAL STUDY; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; RADIOGRAPHY; TREATMENT OUTCOME; ULTRASTRUCTURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HUMANS; INFLIXIMAB; LONGITUDINAL STUDIES; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84943746635     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4152     Document Type: Article

References (35)

1. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology. 1997;112(5):1710-1713.
2. Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Makitie O. Compromised peak bone mass in patients with inflammatory bowel disease-A prospective study. J Pediatr. 2014;164(6):1436-1443. e1.
3. Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology. 2009;136(1):123-130.
4. Tsampalieros A, Lam CK, Spencer JC, et al. Long-term inflammation and glucocorticoid therapy impair skeletal modeling during growth in childhood Crohn disease. J Clin Endocrinol Metab. 2013; 98(8):3438-3445.
5. Vazquez MA, Lopez E, Montoya MJ, Giner M, Perez-Temprano R, Perez-Cano R. Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: A prospective case-control study. BMC Gastroenterol. 2012;12:47.
6. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133(10): 795-759.
7. Leonard MB, Elmi A, Mostoufi-Moab S, et al. Effects of sex, race, and puberty on cortical bone and the functional muscle bone unit in children, adolescents, and young adults. J Clin Endocrinol Metab. 2010;95(4):1681-1689.
8. Osta B, Benedetti G, Miossec P. Classical and Paradoxical Effects of TNF-alpha on Bone Homeostasis. Front Immunol. 2014;5:48.
9. Lane NE, Yao W. Glucocorticoid-induced bone fragility. Ann N Y Acad Sci. 2010;1192:81-83.
10. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27(3):651-662.
11. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014;146(2):383-391.
12. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52(1):31-37.
13. Augustine MV, Leonard MB, Thayu M, et al. Changes in vitamin D-related mineral metabolism after induction with anti-tumor necrosis factor-alpha therapy in Crohn's disease. J Clin Endocrinol Metab. 2014;99(6):E991-E998.
14. Thayu M, Denson LA, Shults J, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology. 2010;139(2):430-438.
15. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12(4):439-447.
16. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc. 1980; 9(3):271-280.
17. Lee DY, Wetzsteon RJ, Zemel BS, et al. Muscle Torque Relative to Cross-Sectional Area and the Functional Muscle-Bone Unit in Children and Adolescents with Chronic Disease. J Bone Miner Res. 2015;30(3):563-571.
18. Leonard MB, Zemel BS, Wrotniak BH, et al. Tibia and radius bone geometry and volumetric density in obese compared to non-obese adolescents. Bone. 2015;73:69-76.
19. Kontulainen SA, Johnston JD, Liu D, Leung C, Oxland TR, McKay HA. Strength indices from pQCT imaging predict up to 85% of variance in bone failure properties at tibial epiphysis and diaphysis. J Musculoskelet Neuronal Interact. 2008;8(4):401-409.
20. Adams JE, Engelke K, Zemel BS, Ward KA. Quantitative computer tomography in children and adolescents: The 2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014;17(2):258-274.
21. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: Improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109(1):45-60.
22. Cole TJ. TheLMSmethod for constructing normalized growth standards. Eur J Clin Nutr. 1990;44(1):45-60.
23. Tuchman S, Thayu M, Shults J, Zemel BS, Burnham JM, Leonard MB. Interpretation of biomarkers of bone metabolism in children: Impact of growth velocity and body size in healthy children and chronic disease. J Pediatr. 2008;153(4):484-490.
24. Mostoufi-Moab S, Brodsky J, Isaacoff EJ, et al. Longitudinal assessment of bone density and structure in childhood survivors of acute lymphoblastic leukemia without cranial radiation. J Clin Endocrinol Metab. 2012;97(10):3584-3592.
25. Wetzsteon RJ, Zemel BS, Shults J, Howard KM, Kibe LW, Leonard MB. Mechanical loads and cortical bone geometry in healthy children and young adults. Bone. 2011;48(5):1103-1108.
26. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011; 26(2):229-238.
27. Rauch F, Travers R, Glorieux FH. Cellular activity on the seven surfaces of iliac bone: A histomorphometric study in children and adolescents. J Bone Miner Res. 2006;21(4):513-519.
28. Seeman E. Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab. 2001;86(10):4576-4584.
29. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol. 2006; 40(1):55-63.
30. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004;20(6):607-614.
31. Miheller P, Muzes G, Rácz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis. 2007;13(11):1379-1384.
32. Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: A prospective study. Aliment Pharmacol Ther. 2004;20(8):851-857.
33. Veerappan SG, O'Morain CA, Daly JS, Ryan BM. Review article: The effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33(12):1261-1272.
34. Laakso S, Valta H, Verkasalo M, Toiviainen-Salo S, Viljakainen H, Mäkitie O. Impaired bone health in inflammatory bowel disease: A case-control study in 80 pediatric patients. Calcif Tissue Int 2012; 91(2):121-130.
35. Leblanc CM, Ma J, Scuccimarri R. A154: Glucocorticoid therapy and the risk of incident vertebral fracture in children with rheumatic disorders. Arthritis Rheumatol. 2014;66 Suppl 11:S199-S200.